NORTHERN-DATA-AG
21.7.2020 07:34:11 CEST | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87 ), one of the world's largest providers of high-performance-computing (HPC) solutions, has developed proprietary HPC services in cooperation with the leading Taiwanese computer hardware manufacturer Gigabyte Technology (Taiwan Stock Exchange: 2376, ISIN: TW0002376001 ).
Northern Data's partnership with Gigabyte covers the production, supply and combination of components, where Northern Data tests specific processors (GPUs, CPUs, etc.) and selects them for the respective applications and Gigabyte combines these processors with its specialised server architecture. In doing so, Gigabyte adjusts the GPU clusters developed by Northern Data to meet all of Northern Data's technical requirements. A GPU cluster is a computer network in which each node (processing unit) is equipped with several Graphic Processing Units (GPU). The high-density GPU clusters used in these processes are specially designed for high-performance-computing (HPC) applications.
The server architecture created on this basis is the foundation for so-called distributed computing. Distributed computing involves running software across multiple computer systems working in parallel, in order to increase their efficiency, reliability and performance. With these new, tailor-made high-density GPU clusters, Northern Data can meet the highly specific requirements of their customers, providing them with the required computing power for their respective HPC applications as easily and efficiently as possible. This service will then be used in Northern Data's data centers for individually developed customer solutions.
GPU-based, parallel processing of data enables highly complex, computationally intensive HPC applications to be executed efficiently, reliably and quickly, particularly in the domains of artificial intelligence and rendering.
This combination of Gigabyte's expertise in manufacturing HPC hardware and Northern Data's experience in managing and orchestrating large-scale facilities (with proprietary AI software and its own thermal management system) opens up new opportunities for Northern Data customers to scale their operations even further than before. Northern Data distinguishes itself from other providers by the composition and combination of hardware and software, the way it is made available and, above all, by the favourable pricing for customers.
"The demand for HPC is booming; the rendering and AI sectors are enormous growth markets. We are pleased to have Gigabyte Technologies, one of the leading suppliers in the young HPC sector, on board as our development partner, and we are now excited to announce this business partnership," explains Aroosh Thillainathan, CEO of Northern Data AG, and continues: "We have already worked together on various GPU-based HPC projects, as we believe that Gigabyte's servers are among the best hardware for HPC in the world. Hence, we are very pleased to deepen our partnership with a manufacturer with this level of expertise and to have them accompany our R&D process. Gigabyte is the right strategic partner to help us make the concept of distributed computing a reality for many HPC applications".
Northern Data CFO Mathis Schultz adds: "So far, our customers are predominantly in the bitcoin mining sector, which was the first mass-scale HPC application. But the demand from other sectors is growing rapidly, accelerated in part by the Covid-19 crisis. The partnership with Gigabyte Technologies allows us to build out our market-leading position with bitcoin mining clients, into new sectors."
And Thomas Yen, European head of Gigabyte Technologies explains: "We are pleased to now officially announce our partnership with Northern Data. We see great potential in our jointly-designed GPU clusters. We are excited to work closely with Northern Data as a strategic partner and high-potential customer in the field of HPC."
About Northern Data:
Northern Data AG builds and offers global infrastructure solutions in the field of high-performance computing (HPC), offering solutions in the fields of machine learning and artificial intelligence, big data analytics, blockchain applications, game streaming and more. Operating internationally the company evolved from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and is now a recognized leader in the provision of HPC solutions worldwide. The company offers HPC solutions, both stationary in large state-of-the-art data centers as well as in high-tech mobile data centers, which can be deployed in any location worldwide. In doing so, it combines self-developed software and hardware with novel concepts to ensure a sustainable and reliable energy supply. In Texas, Northern Data is running the USA's largest HPC data center and, at the same time, the world's largest dedicated HPC facility. Further information can be found at www.northerndata.de .
About Gigabyte Technology Co., Ltd.
Gigabyte Technology Co., Ltd. is a Taiwan-based company principally engaged in the production, processing and sales of information technology (IT) products. The company provides computer motherboards, three dimensional (3D) display graphic cards, laptops, tablets, personal computers (PCs), servers, smart phones, broadband network devices and wireless communication products, computer peripherals and network storage products. It distributes its products mainly within Taiwan, as well as to the rest of Asia, Europe and the Americas.
Disclaimer:
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice.
| Language: | English |
| Company: | Northern Data AG |
| Thurn-und-Taxis-Platz 6 | |
| 60313 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
| EQS News ID: | 1097883 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005840/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
